Side-effect free RNA therapeutics active only in diseased cells

SRTD biotech secures seed financing

18-Nov-2024 - Jülich-based biotech start-up SRTD biotech GmbH has successfully closed a seven-figure seed financing round. The company will use the fresh capital to accelerate the development of novel RNA therapeutics. Based on a proprietary platform technology, SRTD biotech aims to develop highly efficient ...

A promising target for new RNA therapeutics now accessible

Chemists have identified the first inhibitors of the cancer-related RNA-modifier METTL16 and have thus taken a first step towards new therapeutic options

12-Apr-2024 - Only recently, a new era in medicine began with the first RNA vaccines. These active substances are modified RNAs that trigger immune responses of the human immune system. Another approach in RNA medicine targets the body's own RNA and its protein modulators by specifically tailored active ...

Ethris and Heqet Therapeutics announce Collaboration

Collaboration will harness the potential of non coding RNAs (ncRNAs) in regenerating heart tissue

14-Nov-2023 - Ethris GmbH and Heqet Therapeutics, a biotechnology spin-out company from King’s College London active in the field of regenerative medicine, announced a collaboration agreement to harness the potential of ncRNA for heart tissue regeneration following acute myocardial infarction (heart attack) ...

Helping the human body to fight diseases

Research into and development of mRNA-based therapeutics by a consortium of universities, the Fraunhofer-Gesellschaft, and BioNTech

16-Jun-2023 - A new funding program of the German Federal Ministry for Economic Affairs and Climate Action (BMWK) aiming to improve production capacities and fostering research into and the development of specialty lipids and other auxiliaries used in mRNA vaccines and mRNA pharmaceutical will give funding to ...

Use of Artificial Intelligence in Drug Development

WACKER, CordenPharma, LMU and HU Berlin Train Machine Learning Algorithm for the Formulation of RNA Actives

03-Apr-2023 - Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), Wacker Chemie AG and CordenPharma International GmbH have launched a project to accelerate the development of RNA-based drugs. The aim is to develop a new generation of lipid nanoparticles ...

CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer

The RNA Printer is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics

02-Mar-2022 - CureVac N.V. announced that it has established CureVac RNA Printer GmbH, a fully-owned CureVac company to advance The RNA Printer®. The RNA Printer® is CureVac’s solution for integrated and automated manufacturing of GMP-grade RNA vaccines and therapeutics. The new entity is designed as a ...

AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus

14-Feb-2022 - AiCuris Anti-infective Cures AG (AiCuris) and Hybridize Therapeutics (Hybridize) announced that they have entered into a worldwide licensing agreement for Hybridize’s BK virus (BKV) program. The licensed program is based on a novel RNA-based therapeutic approach developed by Hybridize. Under the ...

A spray to protect against lung damage from Covid-19

Startup develop an RNA-based drug

18-Jan-2022 - rnatics, a startup at the Technical University of Munich (TUM), has created an RNA-based drug to prevent lung damage from infections as seen in serious Covid-19 cases. The Federal Ministry of Education and Research (BMBF) is providing 7 million euros in funding to support the development of the ...

Catch me if you can: how mRNA therapeutics are delivered into cells

Novel insights into the development of RNA therapeutics towards efficient delivery and lower dosages

13-Dec-2021 - Researchers have found where and how mRNA arrives in a cell to modify or deliver genetic information, a crucial process for the development of novel therapies. In recent years, ribonucleic acid (RNA) has emerged as a powerful tool for the development of novel therapies. RNA is used to copy ...

Rapid therapeutic approaches against viral diseases

Research team with new development pipeline for RNA-based drugs successful in Europe-wide competition

10-Dec-2021 - Viruses are a major problem for human health worldwide - and not just since the outbreak of the SARS-CoV2 pandemic. Despite successful vaccine development, there are still no effective drugs for most viral diseases. This should change as quickly as possible. With the project "iGUARD (integrated ...